A detailed history of Ironwood Investment Management LLC transactions in Calliditas Therapeutics Ab stock. As of the latest transaction made, Ironwood Investment Management LLC holds 25,627 shares of CALT stock, worth $1.03 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
25,627
Previous 25,511 0.45%
Holding current value
$1.03 Million
Previous $535,000 86.73%
% of portfolio
0.56%
Previous 0.27%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 16, 2024

BUY
$17.65 - $41.41 $2,047 - $4,803
116 Added 0.45%
25,627 $999,000
Q1 2024

May 15, 2024

BUY
$20.04 - $25.66 $1,523 - $1,950
76 Added 0.3%
25,511 $535,000
Q4 2023

Feb 14, 2024

SELL
$15.79 - $28.99 $19,784 - $36,324
-1,253 Reduced 4.69%
25,435 $654,000
Q3 2023

Nov 16, 2023

SELL
$15.68 - $20.38 $8,247 - $10,719
-526 Reduced 1.93%
26,688 $487,000
Q2 2023

Aug 11, 2023

SELL
$15.7 - $25.61 $9,121 - $14,879
-581 Reduced 2.09%
27,214 $431,000
Q1 2023

May 15, 2023

BUY
$16.8 - $25.24 $24,964 - $37,506
1,486 Added 5.65%
27,795 $666,000
Q4 2022

Jan 31, 2023

SELL
$11.5 - $19.6 $27,979 - $47,686
-2,433 Reduced 8.46%
26,309 $447,000
Q3 2022

Nov 14, 2022

SELL
$14.12 - $22.49 $296 - $472
-21 Reduced 0.07%
28,742 $436,000
Q2 2022

Aug 12, 2022

BUY
$12.85 - $20.36 $12 - $20
1 Added 0.0%
28,763 $511,000
Q1 2022

May 10, 2022

BUY
$15.14 - $25.55 $22,634 - $38,197
1,495 Added 5.48%
28,762 $551,000
Q4 2021

Feb 10, 2022

SELL
$15.04 - $26.32 $8,557 - $14,976
-569 Reduced 2.04%
27,267 $675,000
Q3 2021

Nov 12, 2021

BUY
$21.03 - $33.19 $251,224 - $396,487
11,946 Added 75.18%
27,836 $602,000
Q2 2021

Aug 16, 2021

BUY
$26.02 - $31.17 $413,457 - $495,291
15,890 New
15,890 $468,000

Others Institutions Holding CALT

About Calliditas Therapeutics AB


  • Ticker CALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,624,800
  • Market Cap $1.06B
  • Description
  • Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...
More about CALT
Track This Portfolio

Track Ironwood Investment Management LLC Portfolio

Follow Ironwood Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ironwood Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ironwood Investment Management LLC with notifications on news.